Dr Richard Bogle PhD FRCP FESC FACC DHMSA
Consultant Cardiologist
  • Home
  • NHS Practice
    • NHS Practice
    • St Helier Hospital
    • Epsom Cardiac Day Unit
    • St George's Hospital Radial Lounge
    • Echocardiography
  • Biography
    • Qualifications
    • About me >
      • Curriculum vitae
    • Appraisal and Revalidation
    • BCIS Angioplasty Audit
    • Publications
    • Recent abstracts
    • Research
    • Charitable activity
  • The Heart
    • Cardiac Investigations >
      • AliveCor ECG monitor
      • Guide to investigations for suspected angina
      • CT calcium scoring
      • Electrocardiogram (ECG)
      • Exercise treadmill test
      • Echocardiogram
      • Valve disease
      • Coronary Angiography
      • Pressure Wire Studies
      • Intra-vascular Ultrasound
    • Arrhythmias >
      • Atrial fibrillation >
        • Stroke Risk in AF
        • New Oral Anticoagulants
        • Presentations on AF
      • Atrial flutter
      • Pre-excitation syndromes
      • Ventricular ectopic beats
      • Ventricular arrhythmias
      • Pacemaker
      • DC Cardioversion
    • Cardiomyopathy
    • Coronary heart disease >
      • Cardiac syndrome X
      • Coronary Angioplasty
      • Coronary bypass surgery
    • Dizziness and blackouts
    • Fitness to fly
    • Fitness to drive
    • Heart Failure
    • Hypertension >
      • Patients guide to blood pressure medication
      • Home blood pressure monitors
      • Hypertension diet
      • Laragh's method
      • Renal sympathetic ablation for hypertension
      • Conn's Syndrome
    • Heart Screening >
      • Sports Cardiology
      • Cardiovascular Disease Risk
    • Medications >
      • Glyceryl trinitrate
    • Patient information leaflets
  • News and Links
  • Miscellany
    • History of Medicine
    • History of Coronary Angiography and Angioplasty
    • Stamps in Cardiology
    • A History of Medicine in 100 Objects
    • BSE Acceditation Course Introduction
    • BSE Acceditation Course Physics
    • BSE Acceditation Course Anatomy and Function
    • BSE Acceditation Course Mitral
    • BSE Acceditation Course Aortic
    • BSE Acceditation Course Congenital
    • BSE Acceditation Course Pericardium
  • Blog
  • RACPC Form
  • Cardiology Teaching St Helier Hospital

Devices and Desires

11/1/2014

1 Comment

 
Picture
In December 2009 The Telegraph ran an article describing a revolutionary new procedure which was aimed to be able to effectively cure high blood pressure. Like many people I was excited to find out more. A clinical trial been published in April 2009 in the Lancet describing the effects of destroying the nerves which supply the kidneys in 50 patients with resistant hypertension. This observational study had shown impressive and sustained blood-pressure reduction without serious adverse events. Following that a randomised clinical trial of 110 patients was started and the Telegraph article was prompted by the first patient in the UK being treated at the London Chest Hospital as part of the trial. When the study was finally published in December 2010 again it showed impressive and sustained reductions in blood pressure. These results stimulated excitement amongst interventional cardiologists who wanted access to this new treatment for their patients. Research was quoted by experts in the field estimating that there were huge numbers of patients with resistant hypertension for whom this therapy was potentially an option. Ardian, the company which made the ablation catheter, was valued at 800 million dollars and rapidly acquired by Medtronic one of the largest medical device companies in the world.

Ablation devices were rapidly and widely promoted in Europe. Courses and international meetings were established by proponents of the device and sponsored by the device company. Reputations and CVs of the organisers and speakers were enhanced and by August 2012 it was though that over 5000 procedures had been performed. In particular German cardiologists embraced the technology with hundreds of patients being treated. Enthusiasm spread and papers started to appear proposing that renal denervation might be a potential treatment for metabolic syndrome, type 2 diabetes, sleep apnoea and heart failure. Much of this based on uncontrolled studies in a few highly selected patients. It all seemed to good to be true.

UK cardiologists, including myself, started to work out how they could begin to perform this novel procedure. Interventional cardiologists like technology and the prospect of being able to perform a new procedure was very attractive. In many cases charitable funding was raised to purchase the catheters and ablation system. Collaborations were established between radiologists, hypertension experts and cardiologists, a NICE technology appraisal was published, followed by guidelines from the British Hypertension Society and the prospect of "Commission by Evaluation" from NHS England.

Centres, including my own at St Helier Hospital in Carshalton, started to perform the procedure in small numbers.  Our initial enthusiasm for the procedure was tempered by a difficulty in finding the apparently huge number of patients we were told had resistant hypertension. We were referred many patients for evaluation but usually simple medication adjustment such as the addition of spironolactone or treatment of other factors such as sleep apnoea were able to control the blood pressure. Sometimes patients simply had white coat hypertension and proper assessment with ambulatory monitoring revealed well controlled blood pressure. Sometimes the patient did have resistant hypertension but the renal artery anatomy wasn't suitable for ablation. Overall only about 1 in 10 patients we screened were suitable and we started to think that the epidemic of resistant hypertension (defined in guidelines as BP>140mmHg on 3 drugs including a diuretic but for the purposes of the denervation trials a BP threshold of >160mmHg was required) did not really exist.

In the USA things were a little different. The Food and Drug Administration (FDA) concluded that the clinical trials which Ardian had performed were not adequate for licencing the technology since there was no sham treated group. Without this it is possible that significant bias has crept into the trials especially when the end point being measured was office blood pressure. The FDA required a double blind, sham controlled trial and we all awaited eagerly for the results. This week our wait ended earlier than expected when Medtronic put out a press release to say that their pivotal trial had failed to meet its primary efficacy endpoint. In other words there was no difference in the office blood pressure measurement from baseline to 6 months in patients treated with the ablation versus sham treated patients. Fortunately no safety concerns were raised from the trial. The data and full results have not been published yet and so it is difficult to comment in detail but at this stage it is certainly very disappointing that the blood pressure effects seen previously were not reproduced in a sham controlled double blind clinical trial.

There are two lessons here. First, the placebo effect and bias are strong factors which influence clinical outcomes. The bigger the procedure, the more invasive it is and the more enthusiastic the doctor the greater is the chance of a very significant placebo effect. The only way to avoid this is a sham or placebo controlled trial. Second, it is often said that history repeats itself and there are parallels here with renal artery angioplasty. This procedure started in the 1970s with case series suggesting it reduced blood pressure in everybody with renal artery stenosis. The  first randomized trial was published in 1998 and since then all the trials comparing medical treatment with renal angioplasty were negative.


So where does that leave us with renal denervation. It's early days but we should be cautious and I think that in general renal denervation should now only be performed as part of blinded sham controlled research clinical trials.


1 Comment
Rafael Santamaria
11/2/2014 11:09:45 pm

Thank you for sharing with us your thoughts.
I completely agree with you regarding the lessons we should always keep in mind.

Reply

Your comment will be posted after it is approved.


Leave a Reply.

    RSS Feed

    Picture

    Dr Richard Bogle

    The opinions expressed in this blog are strictly those of the author and should not be construed as the opinion or policy of my employers nor recommendations for your care or anyone else's. Always seek professional guidance instead.

    Archives

    November 2019
    March 2016
    February 2016
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    November 2013
    October 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013

    Categories

    All
    Ablation
    Acute Coronary Syndromes
    Acute Coronary Syndromes
    Adherence
    Angioplasty
    Anticoagulants
    Arrhythmia
    Association
    Atherosclerosis
    Atrial Fibrillation
    Auenbrugger
    Bergamot
    Brugada
    Calcium Channel Blockers
    Cancer
    Cardiovascular Risk
    Chest Pain
    Cholesterol
    Cleveland Street
    Clinical Examination
    Colchicine
    Compliance
    Concordance
    Congenital Heart Disease
    Coronary Artery Disease
    Coronary Artery Disease
    C-reactive Protein
    Decision Aids
    Diet
    Ectopics
    Eggs
    Ezetimibe
    Frailty
    Frank's Sign
    Guidelines
    Hawthorne Effect
    Heart Failure
    History Of Medicine
    Hypertension
    ICD
    Internet
    Interventional Cardiology
    Joseph Rogers
    Lipids
    Malaria
    Marathon
    Medicines
    Nice Guidelines
    Nitrovasodilators
    NOAC
    Nudge
    Nutrition
    OCT
    Palpitations
    Pharmacy
    Pressure Wire
    Proteus
    Salt
    Smoking
    Spironolactone
    Statins
    Statistics
    Stent
    Stress
    Stroke
    Syndrome X
    Takotsubo
    Valve-disease
    Vein Grafts
    Ventricular Ectopics
    VF/VT
    Warfarin
    Weekend Working
    Workhouse

    View my profile on LinkedIn
Return to home page

Privacy Statement
Disclaimer
© Dr Richard Bogle 2020
patient feedback
Photo used under Creative Commons from peddhapati